Influenza virus reassortment

New influenza donor strains for the production of reassortant influenza B viruses are provided.

Influenza virus reassortment

New influenza donor strains for the production of reassortant influenza A viruses are provided.

Reverse genetics methods for virus rescue

A method for rescuing a virus by reverse genetics is provided in which cells are added after transfection.

Influenza virus reassortment

The invention provides reassortant influenza strains.

Influenza virus reassortment

New influenza donor strains for the production of reassortant influenza A viruses are provided.

REVERSE GENETICS METHODS FOR VIRUS RESCUE

A method for rescuing a virus by reverse genetics is provided in which cells are added after transfection.

Influenza virus reassortment

Improved methods for the production of reassortant influenza viruses are provided.

REVERSE GENETICS METHODS FOR VIRUS RESCUE

A method for rescuing a virus by reverse genetics is provided in which cells are added after transfection. 128-. (canceled)29. A method for preparing a viral composition , the method comprising the steps of:(i) transfecting a culture eukaryotic cells with at least one expression construct encoding a viral RNA molecule;(ii) adding untransfected eukaryotic cells to the transfected cells of step (i) to provide a mixture of cells, wherein the untransfected cells are of the same type as the cells of step (i);(iii) culturing the mixture of cells from step (ii) so as to produce viruses in the culture; and,(iv) harvesting viruses, proteins or combination thereof from the culture obtained in step (iii), so as to obtain a viral composition.30. The method of claim 29 , further comprising a step of:(v) purifying the viruses from step (iv) so as to obtain purified virions.31. The method of claim 30 , wherein the virions obtained in step (v) is whole virions.32. The method of claim 30 , further comprising inactivating the viruses or the purified virions.33. The method of claim 31 , further comprising packaging the whole virions in a sterile container.34. The method of claim 33 , wherein the viral composition further comprises an adjuvant.35. A kit comprising the whole virions of .36. The kit of claim 34 , further comprising an adjuvant component provided in a separate container.37. The method of claim 30 , further comprising a step of:treating the purified virions with a detergent so as to obtain split virions.38. The method of claim 37 , further comprising inactivating the split virions.39. The method of claim 37 , further comprising packaging the split virions in a sterile container.40. The method of claim 39 , wherein the viral composition further comprises an adjuvant.41. A kit comprising the split virions of .42. The kit of claim 40 , further comprising an adjuvant component provided in a separate container.43. The method of claim 29 , wherein the proteins of step (iv) are ...

REVERSE GENETICS USING NON-ENDOGENOUS POL I PROMOTERS

Expression of a transgene is driven in a host cell using a pol I promoter which is not endogenous to an organism from the same taxonomic order from which the host cell is derived.

COMPOSITIONS AND METHODS TO INCREASE PRODUCTION

Disclosed herein are methods for increasing protein yield and cellular productivity. Chemical agents facilitate host cell production of biological molecules to increase product yield.

Influenza virus reassortment

New influenza donor strains for the production of reassortant influenza A viruses are provided.

REVERSE GENETICS USING NON-ENDOGENOUS POL I PROMOTERS

Expression of a transgene is driven in a host cell using a pol I promoter which is not endogenous to an organism from the same taxonomic order from which the host cell is derived.

Reverse genetics using non-endogenous pol I promoters

Expression of a transgene is driven in a host cell using a pol I promoter which is not endogenous to an organism from the same taxonomic order from which the host cell is derived.

Influenza virus reassortment

New influenza donor strains for the production of reassortant influenza A viruses are provided.

INFLUENZA VIRUS REASSORTMENT

New influenza donor strains for the production of reassortant influenza A viruses are provided. 1. A reassortant influenza A virus comprising two , three , four , five , or six backbone viral segments from a donor strain , wherein the donor strain is selected from the group consisting of 105p30 and PR8-X and at least one viral segment derived from a second influenza strain.2. The reassortant influenza A virus of wherein at least one backbone viral segment includes a sequence having at least 95% identity to a sequence selected from the group consisting of SEQ ID NOs 9-14 or SEQ ID NOs 17-22.3. The reassortant influenza A virus of wherein at least one backbone viral segment includes the sequence of SEQ ID NO: 17 or SEQ ID NO: 20.4. The reassortant influenza A virus of claim 2 , wherein the virus comprises backbone segments from two or more donor strains.5. The reassortant influenza A virus of claim 4 , wherein the PB1 and the PB2 viral segments are from the same donor strain.6. The reassortant influenza A virus of claim 5 , wherein the PB1 viral segment has at least 95% identity to SEQ ID NO: 18 and the PB2 viral segment has at least 95% identity to SEQ ID NO: 19.7. The reassortant influenza A virus of claim 6 , wherein the virus further comprises a viral segment having at least 95% identity to a sequence selected from the group consisting of SEQ ID NOs 17-22.8. The reassortant influenza A virus of claim 3 , wherein the virus comprises the PB2 segment of SEQ ID NO: 19 claim 3 , the PB1 segment of SEQ ID NO: 18 and the NP segment of SEQ ID NO: 20.9. The reassortant influenza A virus of claim 1 , wherein the virus has the HA segment from a pandemic influenza strain.10. A method of preparing a reassortant influenza virus comprising steps of(i) introducing into a culture host one or more expression construct(s) which encode(s) the viral segments required to produce an influenza virus wherein one or more backbone viral segment(s) is/are from a 105p30 and/or a PR8-X ...

INFLUENZA VIRUS REASSORTMENT

New influenza donor strains for the production of reassortant influenza A viruses are provided. 132-. (canceled)33. A non-naturally occurring reassortant influenza A virus comprising six backbone viral segments , a hemagglutinin (HA) segment , and a neuraminidase (NA) segment , wherein the reassortant influenza A virus comprises PB1 and PB2 viral segments from a same donor strain and (1) the PB1 viral segment comprises a nucleotide sequence that encodes a viral polypeptide with at least 80% identity to SEQ ID NO: 18 and (2) the PB2 viral segment comprises a nucleotide sequence that encodes a viral polypeptide with at least 80% identity to SEQ ID NO: 19.34. The reassortant influenza A virus of claim 33 , wherein the PB1 viral segment comprises a nucleotide sequence that encodes a viral polypeptide with at least 90% identity to SEQ ID NO: 18.35. The reassortant influenza A virus of claim 33 , wherein the PB1 viral segment comprises a nucleotide sequence that encodes a viral polypeptide with at least 99% identity to SEQ ID NO: 18.36. The reassortant influenza A virus of claim 33 , wherein the PB2 viral segment comprises a nucleotide sequence that encodes a viral polypeptide with at least 90% identity to SEQ ID NO: 19.37. The reassortant influenza A virus of claim 33 , wherein the PB2 viral segment comprises a nucleotide sequence that encodes a viral polypeptide with at least 99% identity to SEQ ID NO: 19.38. The reassortant influenza A virus of claim 33 , wherein the PB1 viral segment comprises a nucleotide sequence that encodes a viral polypeptide with at least 90% identity to SEQ ID NO: 18 and the PB2 viral segment comprises a nucleotide sequence that encodes a viral polypeptide with at least 90% identity to SEQ ID NO: 19.39. The reassortant influenza A virus of claim 33 , wherein the PB1 viral segment comprises a nucleotide sequence that encodes a viral polypeptide with at least 99% identity to SEQ ID NO: 18 and the PB2 viral segment comprises a nucleotide sequence ...

REVERSE GENETICS USING NON-ENDOGENOUS POL I PROMOTERS

Expression of a transgene is driven in a host cell using a pol I promoter which is not endogenous to an organism from the same taxonomic order from which the host cell is derived. 1: A host cell comprising at least one expression construct encoding a viral RNA molecule , wherein expression of the viral RNA molecule from the construct is controlled by a pol I promoter which is not endogenous to the host cell's taxonomic order.2: A cell having at least one endogenous pol I promoter which control(s) expression of endogenous rRNA and at least one non-endogenous pol I promoter which control(s) expression of a viral RNA or the complement thereof.3: A method for producing a recombinant virus claim 1 , comprising a step of growing the cell of under conditions where the viral RNA molecule is expressed in order to produce virus.4: The method of further comprising infecting a culture host with the virus produced by growing the cell; culturing the culture host infected with the virus to produce further virus; and purifying the further virus obtained by culturing the infected culture host.5: The method of further comprising preparing a vaccine from the purified further virus.6: The cell of claim 1 , wherein the pol I promoter is a primate pol I promoter and the cell is a non-primate cell.7: The cell of claim 1 , wherein the pol I promoter is a non-canine pol I promoter and the cell is a canine cell.8: The cell of wherein the pol I promoter is a human pol I promoter.9: The cell of wherein the cell is an MDCK cell.10: The cell of wherein the MDCK cell is cell line MDCK 33016 (DSM ACC2219).11: The cell of claim 1 , wherein the cell includes at least one bi-directional expression construct.12: The cell of claim 1 , wherein the expression construct is an expression vector or a linear expression construct.13: The cell of claim 1 , wherein the virus is a segmented virus.14: The cell of claim 1 , wherein the virus is a non-segmented virus.15: The cell of claim 1 , wherein the virus is a ...

INFLUENZA VIRUS REASSORTMENT

New influenza donor strains for the production of reassortant influenza B viruses are provided. 1. A method of preparing a reassortant influenza B virus comprising steps of:(i) introducing into a culture host one or more expression construct(s) which encode(s) the viral segments required to produce an influenza B virus wherein the expression construct(s) encode the HA segment from a first influenza B virus and at least one segment from a second influenza virus comprising (a) the NP and/or PB2 segment from the second influenza B virus which is a B/Victoria/2/87 like strain (optionally B/Brisbane/60/08), or (b) the NP segment from the second influenza B virus which is not B/Lee/40 or B/Ann Arbor/1/66 or B/Panama/45/90; and(ii) culturing the culture host in order to produce a reassortant influenza B virus.2. (canceled)3. The method of claim 1 , wherein the at least one segment from a second influenza virus comprises (b) and the NP and PB2 segments are from the second influenza B virus.4. The method of claim 1 , wherein the at least one segment from a second influenza virus comprises (b) and the second influenza B virus is a B/Victoria/2/87 like strain (optionally B/Brisbane/60/08).5. The method of claim 1 , wherein the PA claim 1 , PB1 claim 1 , PB2 claim 1 , NP claim 1 , NS and M segments are from the second influenza B virus.6. The method of claim 1 , wherein the reassortant influenza B virus comprises backbone segments from two or more influenza B strains.7. The method of claim 6 , wherein at least one backbone segment is from a B/Yamagata/16/88 like strain (optionally B/Panama/45/90).8. A method of preparing a reassortant influenza B virus comprising steps of(i) introducing into a culture host one or more expression construct(s) which encode(s) the viral segments required to produce an influenza B virus comprising (a) the HA segment from a B/Yamagata/16/88 like strain (optionally B/Panama/45/90) and at least one backbone segment from a B/Victoria/2/87 like strain ( ...

Compositions and methods to increase production

Disclosed herein are methods for increasing protein yield and cellular productivity. Chemical agents facilitate host cell production of biological molecules to increase product yield.

INFLUENZA VIRUS REASSORTMENT

New influenza donor strains for the production of reassortant influenza A viruses are provided. 132-. (canceled)33: A reassortant influenza A virus comprising six backbone viral segments , a hemagluttinin (HA) segment and a neuraminidase (NA) segment , wherein the virus comprises backbone segments from two or more donor strains , each donor strain providing more than one backbone segment , further wherein at least one backbone viral segment comprises a nucleotide sequence (a) having at least 95% identity to a sequence selected from the group consisting of SEQ ID NOs: 9-14 or SEQ ID NOs: 17-22 , or (b) that encodes a viral polypeptide having at least 99% sequence identity with an amino acid sequence of a polypeptide encoded by the groups consisting of SEQ ID NOs 9-14 or SEQ ID NOs: 17-22.34: The reassortant influenza A virus of claim 33 , comprising PB1 and PB2 viral segments from the same donor strain.35: The reassortant influenza A virus of claim 34 , wherein:(a) the PB1 viral segment has a nucleotide sequence having at least 95% identity to SEQ ID NO: 18 and the PB2 viral segment comprises a nucleotide sequence having at least 95% identity to SEQ ID NO: 19; or(b) the PB1 viral segment comprises a nucleotide sequence that encodes a viral polypeptide having at least 99% sequence identity with the amino acid sequence of a polypeptide encoded by SEQ ID NO: 18 and the PB2 viral segment comprises a nucleotide sequence that encodes a viral polypeptide having at least 99% sequence identity with the amino acid sequence of a polypeptide encoded by SEQ ID NO: 19.36: The reassortant influenza A virus of claim 35 , wherein the virus comprises:(a) an NS segment comprising a nucleotide sequence (i) having at least 95% identity with the sequence of SEQ ID NO: 22, or (ii) that encodes a viral polypeptide having at least 99% sequence identity with the amino acid sequence of a polypeptide encoded by SEQ ID NO: 22; or(b) an M segment comprising a nucleotide sequence (i) having at ...

INFLUENZA VIRUS REASSORTMENT

The invention provides reassortant influenza strains. 24-. (canceled)5. The chimeric hemagglutinin segment of claim 1 , wherein the segment is (4) and comprises all of the nucleotides of (a) to (v).6. The chimeric hemagglutinin segment of claim 1 , comprising one or more of the 5′-NCR domain of SEQ ID NO: 105; and/or the SP of SEQ ID NO: 106; and/or the TM domain of SEQ ID NO: 107; and/or the CT domain of SEQ ID NO: 108; and/or the 3′-NCR of SEQ ID NO: 109.7. The chimeric hemagglutinin segment of claim 1 , wherein the segment is (4) and the first and the second influenza strains are both influenza A or influenza B viruses.8. The chimeric hemagglutinin segment of claim 1 , wherein the 5′-non-coding region claim 1 , the 3′-non-coding region claim 1 , the signal peptide claim 1 , the transmembrane domain and the cytoplasmic domain are all from the second influenza strain.9. The chimeric hemagglutinin of claim 1 , wherein the segment encodes a protein that does not have tyrosine in the position corresponding to amino acid 545 claim 1 , when aligned to SEQ ID NO: 7.1112-. (canceled)13. The chimeric neuraminidase segment of claim 10 , wherein the segment is (3) and comprises all of the nucleotides of (a) to (q).14. The chimeric neuraminidase segment of claim 10 , comprising one or more of the 5′-NCR domain of SEQ ID NO: 110; and/or the CT domain of SEQ ID NO: 111; and/or the TM domain of SEQ ID NO: 112; and/or the 3′-NCR of SEQ ID NO: 113.15. The chimeric neuraminidase segment of claim 10 , wherein the 5′-non-coding region claim 10 , the 3′-non-coding region claim 10 , the transmembrane domain and the cytoplasmic domain are all from the second influenza strain.16. The chimeric hemagglutinin segment of claim 1 , wherein the second influenza strain is a H1 influenza strain.17. A chimeric hemagglutinin protein encoded by the chimeric hemagglutinin segment of .18. A reassortant influenza virus comprising the chimeric hemagglutinin segment of .19. The reassortant influenza ...

INFLUENZA VIRUS REASSORTMENT

New influenza donor strains for the production of reassortant influenza A viruses are provided. 124-. (canceled)25. A reassortant influenza A virus comprising an HA segment , an NA segment and backbone segments PA , PB1 , PB2 , NP , NS and M , wherein the backbone segments are from two or more donor strains , wherein (a) the HA segment and the PB1 segment are from different influenza A strains with the same influenza virus HA subtype , (b) wherein the HA segment and the PB1 segment are from different influenza A strains with different influenza virus HA subtypes , wherein the PB1 segment is not from an influenza virus with a H3 HA subtype and/or wherein the HA segment is not from an influenza virus with a H1 or H5 HA subtype , or (c) at least one backbone segment is from the A/California/07/09 influenza strain.26. The reassortant influenza A virus of claim 25 , wherein the HA segment and the PB1 segment are from a H1 influenza strain.27. The reassortant influenza A virus of claim 25 , wherein the reassortant influenza A virus comprises (b) and the PB1 segment is from a H1 virus and/or wherein the HA segment is from a H3 influenza vims.28. The reassortant influenza A virus of claim 25 , wherein the reassortant influenza A virus comprises (c) and the at least one backbone segment is the PB1 segment.29. The reassortant influenza A virus of claim 28 , wherein the PB1 segment has at least 95% claim 28 , at least 99% identity claim 28 , or 100% identity with the sequence of SEQ ID NO: 16.30. The reassortant influenza A virus of claim 25 , wherein the reassortant influenza A virus comprises (c) and the HA segment is from a H1 influenza strain.31. The reassortant influenza A virus of claim 25 , wherein the PB1 segment and the PB2 segment are from the same donor strain.32. The reassortant influenza A virus of claim 25 , wherein the segments are selected from the group consisting of:a) the PA segment having at least 95% or 99% identity to the sequence of SEQ ID NO: 1;b) the ...

INFLUENZA VIRUS REASSORTMENT

Improved methods for the production of reassortant influenza viruses are provided. 1. A method of preparing an influenza virus , comprising:a) preparing one or more expression construct(s) which comprise(s) coding sequences for expressing at least one segment of an influenza virus genome;b) introducing into a cell which is not 293T one or more expression construct(s) which encode(s) the viral segments of an influenza virus, wherein at least one expression construct is the expression construct prepared in step (a); andc) culturing the cell in order to produce a reassortant influenza virus from the express construct(s) introduced in step (b);wherein steps (a) to (c) are performed in a time period of 124 hours or less.2. A method of preparing an influenza virus comprising the steps ofa) preparing one or more expression construct(s) which comprise(s) coding sequences for expressing at least one segment of an influenza virus genome;b) introducing into a cell one or more expression construct(s) which encode(s) the viral segments of an influenza virus, wherein at least one expression construct is the expression construct prepared in step (a); andc) culturing the cell in order to produce a reassortant influenza virus from the expression construct(s) introduced in step (b);wherein steps (a) to (c) are performed in a time period of 100 hours or less.3. The method of claim 1 , wherein the cell is a non-human cell or a human non-kidney cell.4. A method of preparing a reassortant influenza virus claim 1 , comprising:a) providing a synthetic expression construct which comprises coding sequences for expressing at least one segment of an influenza virus genome by (i) synthesising a plurality of overlapping fragments of the synthetic expression construct, wherein the overlapping fragments span the complete synthetic expression construct, and (ii) joining the fragments to provide the synthetic expression construct;b) introducing into a cell which is not 293T one or more expression ...

Influenza virus reassortment

New influenza donor strains for the production of reassortant influenza B viruses are provided.

INFLUENZA VIRUS REASSORTMENT

New influenza donor strains for the production of reassortant influenza A viruses are provided. 1. A reassortant influenza A virus comprising backbone segments from two or more donor strains , wherein the HA segment and the PB1 segment are from different influenza A strains with the same influenza virus HA subtype.2. A reassortant influenza A virus comprising backbone segments PA , PB1 , PB2 , NP , NS and M , wherein the backbone segments are from two or more donor strains , wherein the influenza A virus further comprises a HA and a NA segment and wherein the HA and the PB1 segment are from different influenza A strains with the same influenza virus HA subtype.3. The reassortant influenza A virus of claim 1 , wherein the HA segment and the PB1 segment are from a H1 influenza strain.4. A reassortant influenza A virus comprising backbone segments from two or more donor strains claim 1 , wherein the HA segment and the PB1 segment are from different influenza A strains with different influenza virus HA subtypes claim 1 , wherein the PB1 segment is not from an influenza virus with a H3 HA subtype and/or wherein the HA segment is not from an influenza virus with a H1 or H5 HA subtype.5. The reassortant influenza A virus of claim 4 , wherein the PB1 segment is from a H1 virus and/or wherein the HA segment is from a H3 influenza virus.6. A reassortant influenza A virus comprising backbone segments from two or more donor strains claim 4 , wherein at least one backbone segment is from the A/California/07/09 influenza strain.7. A reassortant influenza A virus comprising backbone segments PA claim 4 , PB1 claim 4 , PB2 claim 4 , NP claim 4 , NS and M claim 4 , wherein the backbone segments are from two or more donor strains and wherein at least one backbone segment is from the A/California/07/09 influenza strain.8. The reassortant influenza virus of claim 7 , wherein the at least one backbone segment is the PB1 segment.9. The reassortant influenza virus of claim 8 , wherein the ...

Influenza virus reassortment

New influenza donor strains for the production of reassortant influenza A viruses are provided.

INFLUENZA VIRUS REASSORTMENT

Improved methods for the production of reassortant influenza viruses are provided. 1. A method of preparing an influenza virus , comprising:a) preparing one or more expression construct(s) which comprise(s) coding sequences for expressing at least one segment of an influenza virus genome or a synthetic expression construct which comprises coding sequences for expressing at least one segment of an influenza virus genome by (i) synthesising a plurality of overlapping fragments of the synthetic expression construct, wherein the overlapping fragments span the complete synthetic expression construct, and (ii) joining the fragments to provide the synthetic expression construct;b) introducing into a cell which is not 293T the one or more expression construct(s) which encode(s) the viral segments of an influenza virus, wherein at least one expression construct is the expression construct prepared in step (a), or the synthetic expression construct prepared in step (a); andc) culturing the cell in order to produce a reassortant influenza virus from the expression construct(s) or the synthetic expression construct introduced in step (b);wherein steps (a) to (c) are performed in a time period of 124 hours or less.2. A method of preparing an influenza virus comprising the steps ofa) preparing one or more expression construct(s) which comprise(s) coding sequences for expressing at least one segment of an influenza virus genome;b) introducing into a cell one or more expression construct(s) which encode(s) the viral segments of an influenza virus, wherein at least one expression construct is the expression construct prepared in step (a); andc) culturing the cell in order to produce a reassortant influenza virus from the expression construct(s) introduced in step (b);wherein steps (a) to (c) are performed in a time period of 100 hours or less.3. The method of claim 1 , wherein the cell is a non-human cell or a human non-kidney cell.45-. (canceled)6. The method of claim 1 , further ...

REASSORTING THE INFLUENZA VIRUS

Influenza virus reassortment

New influenza donor strains for the production of reassortant influenza A viruses are provided.

Influenza virus reassortment

Improved methods for the production of reassortant influenza viruses are provided.

REASSORTING THE INFLUENZA VIRUS

La présente invention concerne de nouvelles souches donneuses de la grippe pour la production de virus de la grippe A réassortis. La présente invention concerne en outre des procédés pour préparer un vaccin antigrippal et des vaccins antigrippaux obtenus par ces procédés. The present invention relates to novel influenza donor strains for the production of reassortant influenza A viruses. The present invention further relates to methods for preparing influenza vaccine and influenza vaccines obtained by these methods.

Immunogenic composition against influenza

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.

influenza b virus rearrangement

resumo “rearranjo de vírus influenza b” novas estirpes dadoras da gripe para a produção de vírus da gripe b recombinante natural são fornecidas. abstract “influenza b virus rearrangement” new influenza donor strains for the production of natural recombinant influenza b virus are provided.

Influenza b virus reassortment.

Se proporcionan nuevas de cepas donadoras de influenza para la producción de virus de influenza B reordenantes.

Influenza virus reassortment

New influenza donor strains for the production of reassortant influenza A viruses are provided.

Influenza virus reassortment

Immunogenic composition against influenza

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.

Influenza B virus reassortment

New influenza donor strains for the production of reassortant influenza B viruses are provided.

Reverse genetics using non-endogenous pol-I promoters

Reverse genetics using non-endogenous pol i promoters

Improved reverse genetics methods for virus rescue

A method for rescuing a virus by reverse genetics is provided in which cells are added after transfection.

Composição imunogênica contra gripe

composição imunogênica contra gripe. a invenção refere-se a composições e métodos para a preparação, fabricação e uso terapêutico de vacinas de ácido ribonucleico compreendendo moléculas de polinucleotídeo codificando um ou mais antígenos da gripe, tais como antígenos hemaglutinina.

Compositions and methods to increase production

Disclosed herein are methods for increasing protein yield and cellular productivity. Chemical agents facilitate host cell production of biological molecules to increase product yield.

Composiciones y metodos para incrementar la produccion.

Se describen en la presente métodos para incrementar el rendimiento de la proteína y productividad celular. Los agentes químicos facilitan la producción de células hospederas de moléculas biológicas para incrementar el rendimiento del producto.

Combination vaccines against coronavirus infection, influenza infection, and/or rsv infection

This disclosure relates to the field of RNA to prevent or treat multiple infectious agents. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection, influenza infection, and/or RSV infection and inducing effective coronavirus, influenza virus, and/or RSV antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject (i) a bivalent RNA vaccine encoding peptides or proteins comprising epitopes of SARS-CoV-2 spike proteins (S proteins) and (ii) a tetravalent RNA vaccine encoding peptides or proteins comprising epitopes of hemagglutinin (HA), for inducing an immune response against coronavirus S proteins, in particular S proteins of SARS-CoV-2, and influenza proteins, in particular HA proteins of type A and type B influenza viruses, in the subject.

Immunogenic compositions against influenza and rsv

The present disclosure relates to compositions comprising RNA molecules encoding an antigen derived from influenza, wherein the RNA is formulated in a lipid nanoparticle (LNP), and wherein the composition further includes a polypeptide antigen derived from respiratory syncytial virus (RSV). The composition may be used for the prevention of illnesses induced by influenza and RSV infection.

Immunogenic composition against influenza

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.

Composición inmunogénica contra la influenza

La invención se refiere a composiciones y métodos para la preparación, fabricación y uso terapéutico de vacunas de ácido ribonucleico que comprenden moléculas polinucleotídicas que codifican uno o más antígenos de la influenza, como los antígenos de hemaglutinina.

Immunogenic composition against influenza

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.

Immunogenic composition against influenza

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.

Compositions and methods to increase production

Compositions and methods to increase production

Disclosed herein are methods for increasing protein yield and cellular productivity. Chemical agents facilitate host cell production of biological molecules to increase product yield.

Métodos para produzir proteínas recombinantes ou partículas virais, proteína de influenza ou cepa de influenza b e métodos para produzir vacina de influenza

composições e métodos para aumentar a produção. são aqui revelados métodos para aumento do rendimento de proteína e produtividade celular. agentes químicos facilitam a produção pela célula hospedeira de moléculas biológicas para aumentar o rendimento de produto.

Compositions and methods to increase production

Disclosed herein are methods for increasing protein yield and cellular productivity. Chemical agents facilitate host cell production of biological molecules to increase product yield.

Influenza virus reassortment

Immunogenic compositions against influenza and rsv

The present disclosure relates to compositions comprising RNA molecules encoding an antigen derived from influenza, wherein the RNA may be formulated in a lipid nanoparticle (LNP), and wherein the composition further includes a polypeptide antigen derived from respiratory syncytial virus (RSV) and/or RNA molecules encoding an antigen derived from RSV, wherein the RSV RNA may be may be formulated in an LNP. The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the prevention of influenza and RSV infection-induced illness.

Composicion inmunogenica contra la influenza.

La invención se refiere a composiciones y métodos para la preparación, fabricación y uso terapéutico de vacunas de ácido ribonucleico que comprenden moléculas polinucleotídicas que codifican uno o más antígenos de la influenza, como los antígenos de hemaglutinina.

Immunogenic compositions and uses thereof

The present disclosure relates to compositions comprising RNA molecules encoding an antigen derived from influenza, wherein the RNA may be formulated in a lipid nanoparticle (LNP), and wherein the composition further includes a polypeptide antigen derived from respiratory syncytial virus (RSV) and/or RNA molecules encoding an antigen derived from RSV, wherein the RSV RNA may be may be formulated in an LNP. The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the prevention of influenza and RSV infection-induced illness.

Immunogenic compositions and methods of inducing an immune response against varicella zoster virus

The present disclosure provides for methods of inducing an immune response against varicella zoster virus (VZV) in a human subject. The methods provided herein comprise administering immunogenic compositions (e.g., vaccines) comprising RNA molecules formulated in a lipid nanoparticle to a human subject. The present disclosure further relates to the use of immunogenic compositions for preventing or treating of herpes zoster in a human subject.

Immunogenic composition against influenza

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.

Reverse genetics using non-endogenous pol i promoters

Expression of a transgene is driven in a host cell using a pol I promoter which is not endogenous to an organism from the same taxonomic order from which the host cell is derived.

Reverzna genetika korištenjem ne-endogenih pol i promotora

Reverse genetics using non-endogenous pol i promoters

Genética inversa usando promotores no endógenos de pol l

Un procedimiento para producir un virus recombinante, que comprende la etapa de cultivar una célula huéspedcanina que comprende al menos una construcción de expresión que codifica una molécula de ARN viral, en el que laexpresión de la molécula de ARN viral a partir de la construcción está controlada por un promotor de primate de pol Ien condiciones en las que se expresa la molécula de ARN viral para producir virus.

Nucleic acids and uses thereof

Self-amplifying RNA (saRNA) molecules encoding an influenza virus antigen and methods of use thereof are disclosed herein.

Immunogenic composition against influenza

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.

非内因性ｐｏｌＩプロモーターを使用した逆遺伝学

【課題】非内因性ｐｏｌＩプロモーターを使用した逆遺伝学の提供。 【解決手段】宿主細胞が由来するのと同じ分類学上の目の生物にとって内因性ではないｐｏｌＩプロモーターを使用して、宿主細胞中で導入遺伝子の発現が促進される。一実施形態では、本発明は、１つまたは複数の発現構築物を含む宿主細胞を提供し、その発現構築物からのＲＮＡ分子の発現は、宿主細胞の目にとって内因性ではないｐｏｌＩプロモーターによって調節される。本発明は、（ｉ）目的の導入遺伝子の発現が第１の生物由来のｐｏｌＩプロモーターによって促進される発現構築物を調製するステップと、（ｉｉ）第１の生物と異なる分類学上の目由来である宿主細胞中にステップ（ｉ）の発現構築物を導入するステップとを含む、宿主細胞中でＲＮＡを発現させるプロセスをさらに提供する。 【選択図】図５

Modulating the innate immunity of rna

The present disclosure provides methods and compositions for modulating the innate immunity to exogenous ribonucleic acid (RNA) when administered to a subject in need thereof. More particularly, the disclosure provides compositions comprising RNA encoding at least one antigen or therapeutic protein, and at least one compound that modulates the innate immunity to such RNA when administered to a subject in need thereof. The disclosure further provides methods of using such compounds to modulate the innate immunity of such compositions.